Compare · NYMX vs ORKA
NYMX vs ORKA
Side-by-side comparison of Nymox Pharmaceutical Corporation (NYMX) and Oruka Therapeutics Inc. (ORKA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NYMX and ORKA operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA is the larger of the two at $3.86B, about 32.3x NYMX ($119.6M).
- ORKA has hit the wire 11 times in the past 4 weeks while NYMX has been quiet.
- ORKA has more recent analyst coverage (11 ratings vs 0 for NYMX).
- Company
- Nymox Pharmaceutical Corporation
- Oruka Therapeutics Inc.
- Price
- $0.20-19.60%
- $66.01+3.09%
- Market cap
- $119.6M
- $3.86B
- 1M return
- -
- +2.23%
- 1Y return
- -
- +425.14%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 0
- 11
- Recent ratings
- 0
- 11
Nymox Pharmaceutical Corporation
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. In addition, it offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease. The company was founded in 1989 and is headquartered in Nassau, The Bahamas.
Latest NYMX
- SEC Form 6-K filed by Nymox Pharmaceutical Corporation
- SEC Form 6-K filed by Nymox Pharmaceutical Corporation
- SEC Form 6-K filed by Nymox Pharmaceutical Corporation
- SEC Form 6-K filed by Nymox Pharmaceutical Corporation
- SEC Form 6-K filed by Nymox Pharmaceutical Corporation
- SEC Form 6-K filed by Nymox Pharmaceutical Corporation
- SEC Form 6-K filed by Nymox Pharmaceutical Corporation
- SEC Form 6-K filed by Nymox Pharmaceutical Corporation
- SEC Form 6-K filed by Nymox Pharmaceutical Corporation
- SEC Form 6-K filed by Nymox Pharmaceutical Corporation
Latest ORKA
- Oruka Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 4 filed by Director Dambkowski Carl
- SEC Form 4 filed by Director Kulkarni Samarth
- SEC Form 4 filed by Director Martin Christopher Nathan
- SEC Form 4 filed by Director Ball Kristine M
- SEC Form 4 filed by Director Fairmount Funds Management Llc
- Oruka Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Phase 2 Data could Transform these Biotechs from Clinical Promise to Market Validation
- Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
- Director Dambkowski Carl exercised 62,260 shares at a strike of $7.95 and sold $6,191,366 worth of shares (105,000 units at $58.97) as part of a pre-agreed trading plan, decreasing direct ownership by 37% to 73,743 units (SEC Form 4)